• Avoid Martingale-style doubling down; repeated increases after losses can magnify risk and potentially wipe out your capital.
• Treat bearish comments on DNA, SLS, RXRX, MRNA, and WOLF as unverified views, not automatic short signals; no price targets or clear timing were provided, and shorting volatile stocks can lead to severe losses.
• For biotech investments, prioritize companies with credible clinical evidence, a viable path to FDA approval, and sufficient funding rather than relying on speculative drug claims.
• Build trading discipline by keeping a trade journal, reviewing past trades, and researching companies before taking a position.

Martingale Strategy

• Shkreli said he would not use the Martingale strategy under any circumstances, calling it inferior.
• He warned that repeatedly increasing a position after losses can leave an investor exposed to losing all their money.

Takeaways

• Avoid treating “doubling down” as a reliable way to recover losses; the speaker explicitly rejected the strategy.

NVIDIA (NVDA)

• Shkreli used a short position as an example of how a trade can go badly if the stock keeps rising: if NVIDIA grew 20% per year, a short could eventually lose all its value.
• He noted that the firm did not hold NVIDIA during the trading day discussed, when the stock reached new highs.

Takeaways

• The discussion is a warning about the potentially severe losses from shorting a stock that continues to rise—not a specific price target or a recommendation to buy NVIDIA.

Hims & Hers (HIMS)

• Shkreli said he had no opinion on Hims & Hers at the time—neither bullish nor bearish. The transcript refers to the company as “HIMSS.”

Takeaways

• The speaker offered no actionable view on the stock.

Recursion Pharmaceuticals (RXRX)

• Shkreli said he had been short Recursion for years and described it as an “AI biotech” company he viewed as unconvincing.
• He also called Recursion overvalued as part of a broader group of biotech and AI-related companies he criticized.
• Despite his negative view, he acknowledged that the short had not worked well for him.

Takeaways

• The speaker’s view is bearish, but his own experience shows that a negative thesis does not guarantee a profitable short.

Ginkgo Bioworks (DNA)

• Shkreli described Ginkgo as a “huge short” and called it overvalued.
• He pointed to a sharp recent rise in the share price despite, in his view, no company news explaining the move.
• He said he had shorted the stock on Friday and covered the position.

Takeaways

• The speaker saw a possible short opportunity, but the rapid price movement he described also highlights the risk of trying to trade momentum in a volatile stock.

Moderna (MRNA)

• Moderna was included among the companies Shkreli called “crazy overvalued.”
• He also remarked that the stock was “crapping out a little bit,” describing a decline in the trading session.

Takeaways

• The speaker’s tone was bearish, but he did not give a specific price target, timeline, or detailed company analysis.

Twist Bioscience (TWST)

• Twist was grouped with Ginkgo, Moderna, and Recursion as a company Shkreli considered overvalued.

Takeaways

• The speaker expressed a negative valuation view, but did not provide a specific trade recommendation or supporting company details.

Sellas Life Sciences (SLS)

• Shkreli called SLS an “easy short” and said shorting it was a Wall Street consensus.
• He cited conversations with two leukemia doctors, who estimated a 25% chance that a relevant treatment would work. Shkreli said even that estimate was too generous, though he acknowledged he might be wrong about the drugs.

Takeaways

• The speaker was strongly bearish, but the discussion rests on his interpretation of clinical prospects and doctors’ views—not a stated clinical-trial result or price target.

ACM Research (ACMR)

• Shkreli said he had bought a small amount of ACM Research, a semiconductor company, and described its selloff at that point as happening “for no reason.”
• Later, he highlighted that the stock had been sharply “crushed” and said it could have been shorted as it fell. He also referred to ACMR as a possible source of trading opportunities.

Takeaways

• The comments suggest ACMR may offer short-term trading opportunities, but they do not establish a clear long-term view. The speaker’s small purchase and later short-trading comment reflect a tactical, price-focused approach.

ASML Holding (ASML)

• ASML was the standout winner in the trading-day recap.

Takeaways

• This was a report of one day’s trading performance, not a broader investment thesis or recommendation.

Advanced Micro Devices (AMD)

• Shkreli called AMD “super expensive” and said there were better stocks to short.

Takeaways

• The speaker was negative on valuation but did not present AMD as his preferred short.

Applied Materials (AMAT)

• Shkreli said the trading position in AMAT lost a little money that day.

Takeaways

• The transcript provides only a short-term trading update, not a broader view of the company.

Wolfspeed (WOLF)

• Shkreli called Wolfspeed a “shitty company” and said it was a short.
• He also mentioned the stock in a discussion of less-followed names that smaller traders may be able to trade more easily.

Takeaways

• The speaker’s view was bearish. His comments focused on short-term trading and did not include a price target or a detailed company analysis.

Kulicke and Soffa (KLIC)

• Shkreli said KLIC had reported that its data-center-related revenue had doubled.
• He suggested that if it doubled again, the stock could also double, and noted that fewer people were watching KLIC than some popular stocks.

Takeaways

• The speaker identified revenue growth as a possible catalyst and KLIC as a less-crowded trading idea. The potential for another doubling was hypothetical, not a forecast.

United Microelectronics (UMC)

• Shkreli said the position was profitable and remarked that an investor could sell it.

Takeaways

• This was a brief trading comment, not a broader assessment of UMC or a specific recommendation for all investors.

Seagate Technology (STX)

• Shkreli said the trading desk made a little money on Seagate, though it could have made more.

Takeaways

• The transcript provides only a day-trading update and no longer-term investment view.

SanDisk (SNDK)

• Shkreli said it was difficult to follow SanDisk because “everyone’s on it,” contrasting it with less-followed stocks.
• He also mentioned a small rally in the trading-day recap.

Takeaways

• The comments concern how crowded and difficult the stock may be to trade, not its long-term fundamentals.

Micron Technology (MU), Taiwan Semiconductor (TSM), and SK Hynix

• Shkreli said the trading desk did not have positions in NVIDIA or TSM during a session when those stocks made significant highs. He also mentioned Micron and SK Hynix in the trading recap, without giving a specific investment view on them.

Takeaways

• The transcript does not provide a clear recommendation or fundamental analysis for these companies.

BioNTech (BNTX) and Bristol Myers Squibb (BMY)

• The transcript refers to a PD-L1/VEGF-A bispecific associated with a Bristol Myers and BioNTech collaboration; the treatment name is unclear in the transcript.
• Shkreli said the reported pattern of higher responses at a lower dose made him raise an eyebrow and call the result suspicious.
• Separately, he said he did not know why Bristol Myers was down that day.

Takeaways

• The speaker expressed skepticism about the described dose-response result, but the transcript does not provide enough detail to evaluate the drug or the underlying data.

Cerebras Systems

• Shkreli said that people he considered knowledgeable had told him Cerebras was a short.
• He contrasted that with OpenAI, saying he was unsure about it.

Takeaways

• This was a secondhand, tentative comment—not a detailed short thesis or a specific recommendation.

Costco (COST)

• Shkreli noted that Costco was trading at a price-to-earnings ratio of 44 and asked how the valuation could be justified.
• He answered that Costco’s “unbelievable consistency” was likely behind its high multiple.

Takeaways

• The discussion points to consistency as a possible explanation for Costco’s valuation premium. It does not state whether the speaker considers the stock a buy or a sell.

Pump.fun

• Shkreli said he would trade on Pump.fun if he had time and called it a good source of money.
• He also said the outcome depended on how many copy traders he could sell to, and joked about “rugging” teenagers.

Takeaways

• The comments describe speculative trading and an intent to profit from other traders’ activity. They do not provide a specific token recommendation, and the speaker’s remarks underscore the potential for highly adversarial and risky trading.

Biotech and Drug Development

• Shkreli said medicines generally need FDA approval to be worth much, which requires clinical trials and therefore capital.
• He emphasized that raising capital depends on persuading investors that a drug is worth backing, and dismissed advice based on random peptides found online.

Takeaways

• The discussion highlights FDA approval, clinical-trial evidence, and access to capital as important considerations when evaluating drug-development companies. The transcript does not offer a specific biotech investment recommendation.

Other Company Mentions

• Meta (META) and Microsoft (MSFT) were mentioned in connection with efforts to reduce employees’ reliance on Claude; no investment view was given.
• MongoDB (MDB) was mentioned as a stock traded that day, without a clear assessment.
• Texas Instruments (TXN) and Palantir (PLTR) were mentioned without investment analysis.
• Spire Therapeutics (SYRE) was mentioned in connection with an offering; no view on the stock was provided.

Takeaways

• These mentions provide news or trading context, but the transcript does not establish a bullish or bearish thesis for these companies.

Trading Process

• Shkreli recommended reading trading books, reviewing trades, keeping a trade journal, and studying more companies.
• He suggested that smaller traders may be able to trade less-followed stocks more easily than heavily watched names.

Takeaways

• The actionable guidance was focused on trading discipline and preparation: review past decisions, maintain a journal, and learn the companies before trading them.